The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults
- PMID: 23360833
- PMCID: PMC3750101
- DOI: 10.1097/INF.0b013e318286c793
The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults
Abstract
Background: In HIV-infected adults, we and others have shown that vitamin D deficiency is independently associated with increased carotid intima-media thickness (cIMT), a surrogate marker for cardiovascular disease (CVD). This study explored for the first time the relationship between vitamin D and CVD risk in HIV-infected youth.
Methods: This is a cross-sectional assessment of cIMT, inflammation, metabolic markers and vitamin D status in HIV-infected youth and healthy controls. We measured serum 25-hydroxyvitamin D (25(OH)D), fasting lipids, insulin, glucose, inflammatory markers and cIMT.
Results: Thirty HIV-infected subjects and 31 controls were included. Among HIV-infected subjects, median age was 11 years (37% males; 73% black; similar to controls). HIV-infected subjects' mean (standard deviation) serum 25(OH)D was 24 (35) ng/mL; 70% had 25(OH)D<20 ng/mL (deficient), 23% between 20-30 ng/mL (insufficient) and 7%>30 ng/mL (sufficient); proportions were similar to controls (P=0.17). After adjusting for season, sex and race, there was no difference in serum 25(OH)D between groups (P=0.11). Serum 25(OH)D was not significantly correlated with cIMT, inflammatory markers or lipids. Serum 25(OH)D was negatively correlated with body mass index, insulin resistance, HIV duration, and cumulative use of antiretroviral therapy, non- and nucleoside reverse transcriptase inhibitors.
Conclusions: Most HIV-infected youth have vitamin D deficiency or insufficiency. Despite no direct association between serum 25(OH)D and cIMT, there were notable associations with some CVD risk factors, particularly inverse correlation with insulin resistance. Studies are needed to determine whether CVD risk, including insulin resistance, could be improved with vitamin D supplementation.
Figures

Similar articles
-
Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial.Osteoporos Int. 2017 Jan;28(1):201-209. doi: 10.1007/s00198-016-3826-x. Epub 2016 Nov 11. Osteoporos Int. 2017. PMID: 27837268 Clinical Trial.
-
Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth.Antivir Ther. 2012;17(6):1069-78. doi: 10.3851/IMP2318. Epub 2012 Aug 16. Antivir Ther. 2012. PMID: 22894927 Free PMC article.
-
25-hydroxyvitamin D is associated with adiposity and cardiometabolic risk factors in a predominantly vitamin D-deficient and overweight/obese but otherwise healthy cohort.J Steroid Biochem Mol Biol. 2017 Oct;173:258-264. doi: 10.1016/j.jsbmb.2016.12.008. Epub 2016 Dec 19. J Steroid Biochem Mol Biol. 2017. PMID: 28007531
-
Vitamin D in HIV-Infected Patients.Curr HIV/AIDS Rep. 2011 Sep;8(3):133-41. doi: 10.1007/s11904-011-0082-8. Curr HIV/AIDS Rep. 2011. PMID: 21647555 Free PMC article. Review.
-
Does sufficient evidence exist to support a causal association between vitamin D status and cardiovascular disease risk? An assessment using Hill's criteria for causality.Nutrients. 2014 Sep 2;6(9):3403-30. doi: 10.3390/nu6093403. Nutrients. 2014. PMID: 25184368 Free PMC article. Review.
Cited by
-
Bone health in HIV-infected children and adolescents.Curr Opin HIV AIDS. 2016 May;11(3):294-300. doi: 10.1097/COH.0000000000000270. Curr Opin HIV AIDS. 2016. PMID: 26890208 Free PMC article. Review.
-
Metabolic complications and treatment of perinatally HIV-infected children and adolescents.J Int AIDS Soc. 2013 Jun 18;16(1):18600. doi: 10.7448/IAS.16.1.18600. J Int AIDS Soc. 2013. PMID: 23782481 Free PMC article. Review.
-
Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial.Osteoporos Int. 2017 Jan;28(1):201-209. doi: 10.1007/s00198-016-3826-x. Epub 2016 Nov 11. Osteoporos Int. 2017. PMID: 27837268 Clinical Trial.
-
Potential Advantages of a Well-balanced Nutrition Regimen for People Living with Human Immunodeficiency Virus Type -1.J AIDS HIV Treat. 2024;6(1):11-27. doi: 10.33696/aids.6.048. J AIDS HIV Treat. 2024. PMID: 38845818 Free PMC article.
-
Vitamin D status and associated factors among HIV-infected children and adolescents on antiretroviral therapy in Kampala, Uganda.PLoS One. 2021 Jun 24;16(6):e0253689. doi: 10.1371/journal.pone.0253689. eCollection 2021. PLoS One. 2021. PMID: 34166428 Free PMC article. Clinical Trial.
References
-
- Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clinical Infectious Diseases. 2007;44:1625–31. - PubMed
-
- Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. The New England journal of medicine. 2007;356:1723–35. - PubMed
-
- Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study AIDS. 2003;17:1179–93. - PubMed
-
- Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196:720–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical